

**27th World Congress on
DIET, NUTRITION AND OBESITY
&
18TH WORLD GASTROENTEROLOGISTS SUMMIT
September 07-08, 2018 Auckland, New Zealand**



Bruce D Given

Arrowhead Pharmaceuticals Inc., USA

Hepatitis B in focus: New biology, new targets and real hope for finite therapy

Drug development work in Chronic Hepatitis B (CHB) has been largely stagnant for the last decade or more. While solid epidemiology work has demonstrated that seroclearance of HbsAg (functional cure) is associated with greatly reduced risk of cirrhosis or HCC, neither interferon therapy nor long-term nucleos(t)ide therapy are associated with meaningful rates of functional cure. With the recent successes achieved in curative treatment of Hepatitis C, the field has returned to curative efforts in CHB and there has been an explosion of pre-clinical drug development against novel targets. As part of this process, new insights have been gained regarding the biology of CHB. This talk will focus on how these new biological insights are translating into new drug discovery efforts, how these new drug classes are performing in the clinic, and the expected role for combining these drugs to achieve meaningful rates of functional cure with finite therapy.

Biography

Bruce D Given has served as COO of Arrowhead Pharmaceuticals since 2011. He has retired as Chairman of the Board for ICON, plc in 2013. He was with Johnson & Johnson for 9 years, with assignments including President, International, Ortho-Clinical Diagnostics and Head of US Marketing & Sales and Research & Development for Janssen Pharmaceutical. He has received his MD with honors from the University of Chicago, completed his Medical Training at University of Chicago and Brigham and Women's Hospital, where he was Clinical Fellow at Harvard Medical School and was on the medical faculty at University of Chicago.

bgiven@arrowheadpharma.com

Notes: